Dashboard/NH

NH

OVERVALUED

Narayana Hrudayalaya

Healthcare · NSE

↓ 55.0% vs fair value

52W Low

₹1,451

+16.2% from low

52W High

₹2,370

-28.9% from high

News sentiment (7 articles)

1 bull4 neutral2 bear

Valuation Gauge

OVERVALUED-55.0% Margin of Safety

OVERVALUEDFAIRLY VALUEDUNDERVALUED

Current Price

₹1,686

Fair Value

₹1,088

Fair Value Analysis

₹1,088

Based on balance sheet strength analysis and earnings growth potential for Healthcare sector companies | CAUTION: ROCE declining (latest 21.4%) — returns on capital are falling; verify this isn't a value trap. | Growth capped at 22.1% (ROE 19.2%×1.15) — historical CAGR exceeds sustainable rate or COVID period unverifiable. | COVID-resilient: PAT dropped from ₹59Cr (FY2019) to ₹-14Cr (FY2021) during COVID but has fully recovered.

Medium confidence

Balance Sheet Value

33% weight

₹412

Growth Valuation

67% weight

₹1,425

Price vs Market

Nifty 50

Shareholding Pattern

Stock Health Score

B+

Financially Healthy

7.6 / 10

Profitability

10/10

ROE of 19.2% is above the Healthcare sector benchmark of 15% — strong returns

Debt & Leverage

10/10

D/E ratio of 0.6x is well within the Healthcare sector norm of 0.8x — strong balance sheet

Valuation vs Peers

10/10

P/E of 42.7x trades at a 73% discount to Healthcare sector median (160x) — attractively valued

Cash Flow

1/10

Negative FCF of ₹-96 Cr — company is consuming more cash than it generates

Earnings Growth

10/10

5yr EPS CAGR of 32.2% is well above the Healthcare sector average of 18.7% — strong growth

Dividend

4/10

Dividend yield of 0.3% is symbolic — low but positive

Sentiment Trend — Last 30 Days

Historical Returns

Key Ratios & Growth

FCF Yield

-1.0%

Free cash flow / market cap

Revenue Growth (YoY)

+61.1%

Year-on-year revenue change

Profit Growth (YoY)

-34.2%

Year-on-year PAT change

Operating Cash Flow

₹986 Cr

TTM cash from operations

Key Financials

EPS (TTM)

₹38.1

P/E Ratio

42.7x

P/B Ratio

8.2x

ROE

19.2%

ROCE

17.8%

Debt / Equity

0.58x

Beta

0.11

Div Yield

0.3%

FCF (Cr)

₹-96 Cr

Revenue (Cr)

₹5,483 Cr

EPS Growth 5Y

32.2%

Mkt Cap (Cr)

₹33,004 Cr

52W High

₹2,370.2

52W Low

₹1,451.1

Book Value/Share

₹198.2

Financial History

Period	Revenue	Op Profit	OPM%	PAT	EPS
TTM	₹6.8K Cr	₹1.5K Cr	22.0%	₹779 Cr	₹38.11
2025-03-31	₹5.5K Cr	₹1.3K Cr	24.0%	₹791 Cr	₹38.66
2024-03-31	₹4.9K Cr	₹1.2K Cr	24.0%	₹790 Cr	₹38.62
2023-03-31	₹4.5K Cr	₹987 Cr	22.0%	₹607 Cr	₹29.67
2022-03-31	₹3.7K Cr	₹664 Cr	18.0%	₹342 Cr	₹16.73
2021-03-31	₹2.6K Cr	₹189 Cr	7.0%	₹-14 Cr	₹-0.70
2020-03-31	₹3.1K Cr	₹434 Cr	14.0%	₹119 Cr	₹5.82
2019-03-31	₹2.9K Cr	₹295 Cr	10.0%	₹59 Cr	₹2.90
2018-03-31	₹2.3K Cr	₹217 Cr	10.0%	₹51 Cr	₹2.51
2017-03-31	₹1.9K Cr	₹236 Cr	13.0%	₹83 Cr	₹4.06
2016-03-31	₹1.6K Cr	₹180 Cr	11.0%	₹21 Cr	₹1.04
2015-03-31	₹1.4K Cr	₹128 Cr	9.0%	₹-19 Cr	₹-0.84
2014-03-31	₹1.1K Cr	₹106 Cr	10.0%	₹29 Cr	₹974.49

Compounded Growth Rates

Sales Growth

3Y+14.4%

5Y+21.3%

10Y+15.4%

Profit Growth

3Y+8.7%

5Y—

10Y+43.5%

EPS Growth

3Y+8.7%

5Y—

10Y+43.4%

Peer Comparison

Healthcare

Stock	Price	Fair Value	MoS%	P/E	ROE	Signal
ALPA Alpa Laboratories Limited	₹62.1	₹198.5	+68.7%	9.4	13.4%	FAIRLY_VALUED
ASTERDM Aster DM Healthcare	₹670	₹1,585.8	+57.8%	103.2	7.9%	UNDERVALUED
UNICHEMLAB Unichem Laboratories Limited	₹300	₹592.5	+49.4%	7.1	12.1%	FAIRLY_VALUED
DCAL Dishman Carbogen Amcis Limited	₹147.6	₹281.2	+47.5%	19.5	1.9%	FAIRLY_VALUED
VIMTALABS Vimta Labs Limited	₹414.8	₹722.6	+42.6%	24.6	16.6%	UNDERVALUED
MOREPENLAB Morepen Laboratories Limited	₹38.4	₹52.8	+27.2%	21	10.8%	FAIRLY_VALUED
INDRAMEDCO Indraprastha Medical Corporation Limited	₹410	₹462.6	+11.4%	20	20.6%	FAIRLY_VALUED
KRONOX Kronox Lab Sciences Limited	₹133	₹130.7	-1.8%	16.9	24.8%	FAIRLY_VALUED